1 day Ago By ABMN Staff
Ovid Therapeutics ( NASDAQ:OVID – Get Free Report ) and Cyclacel Pharmaceuticals ( NASDAQ:CYCC – Get Free Report ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability. Risk & Volatility Ovid Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.
Comparatively, Cyclacel Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Profitability This table compares Ovid Therapeutics and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.
Insider and Institutional Ownership Valuation & Earnings This table compares Ovid Therapeutics and Cyclacel Pharmaceuticals”s revenue, earnings per share (EPS) and valuation. Cyclacel Pharmaceuticals has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings This is a summary of current ratings and price targets for Ovid Therapeutics and Cyclacel Pharmaceuticals, as provided by MarketBeat. Ovid Therapeutics presently has a consensus price target of $4.04, indicating a potential upside of 292.
23%. Cyclacel Pharmaceuticals has a consensus price target of $11.00, indicating a potential upside of 2,844.
33%. Given Cyclacel Pharmaceuticals’ higher probable upside, analysts plainly believe Cyclacel Pharmaceuticals is more favorable than Ovid Therapeutics. Summary Ovid Therapeutics beats Cyclacel Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
About Ovid Therapeutics ( Get Free Report ) Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.
It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc.
The company was incorporated in 2014 and is headquartered in New York, New York. About Cyclacel Pharmaceuticals ( Get Free Report ) Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally.
The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
